PATENT

Application No.: 09/723,713 Amdt. Submitted on June 2, 2003 Reply to Office Action of December 3, 2002

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-32: (Canceled)

- 33. (Currently Amended) A method of preventing or treating a disease characterized by amyloid [deposit] plaques comprising A β peptide, the method comprising administering a polynucleotide encoding at least one antibody chain to the <u>a</u> patient in an effective regime whereby the polynucleotide is expressed to produce the antibody chain and the antibody chain reduces levels of A β in the brain of the patient, wherein the antibody chain binds to an epitope within A β 1-10, and is a chimeric, humanized or human antibody chain.
- 34. (Original) The method of claim 33, wherein the polynucleotide encodes heavy and light chains of the antibody, which polynucleotide is expressed to produce the heavy and light chains in the patient.

35-55: (Canceled)

- 56. (New) The method of claim 33, wherein the antibody is a single-chain antibody.
 - 57. (New) The method of claim 33, wherein the antibody is of IgG1 isotype.
- 58. (New) The method of claim 33, wherein the antibody is expressed in blood cells of the patient.
- 59. (New) The method of claim 58, wherein the polynucleotide encoding the antibody chain is in operable linkage to immunoglobulin or CMV promoter and enhancer elements.
- 60. (New) The method of claim 53, wherein the polynucleotide encodes first and second antibody chains in the same vector.
- 61. (New) The method of claim 53, wherein the antibody chain has the same binding specificity as antibody 10D5.



Application No.: 09/723,713 Amdt. Submitted on June 2, 2003 Reply to Office Action of December 3, 2002

PATENT

- 62. (New) The method of claim 33, wherein the antibody chain has a constant region responsible for effector function.
- 63. (New) The method of claim 33, wherein the nucleic acid is delivered via a virus containing the nucleic acid at a dosage of at least 10⁹ virions.
- 64. (New) The method of claim 33, wherein the antibody is a chimeric antibody.
- 65. (New) The method of claim 33, wherein the antibody is a humanized antibody.
- 66. (New) The method of claim 33, wherein the antibody is a human antibody.
 - 67. (New) The method of claim 33, wherein the antibody is humanized 10D5.

